Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 12, 2014, Pages 3236-3243

  Personne, Yoann ^a   Curtis, Michael A ^a   Wareham, David W ^a   Waite, Richard D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antibiotic synergy; MDR; Novel therapies

Indexed keywords

1 (2,5 DICHLOROPHENYL) 3 (DIMETHYLAMINO)PROPAN 1 ONE; ANTIINFECTIVE AGENT; COLISTIN; HEXAMETAPHOSPHATE SODIUM; SIGNAL PEPTIDASE I; TYPE I SIGNAL PEPTIDASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; MEMBRANE PROTEIN; SERINE PROTEINASE; TYPE I SIGNAL PEPTIDASE;

ACINETOBACTER BAUMANNII; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG POTENCY; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; IC50; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA; WILD TYPE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; INHIBITORY CONCENTRATION 50; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; SERINE ENDOPEPTIDASES;

EID: 84934299919     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku309     Document Type: Article

References (41)

1. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. Paetzel M, Karla A, Strynadka NC et al. Signal peptidases. Chem Rev 2002; 102: 4549-80.
3. Lewenza S, Gardy JL, Brinkman FS et al. Genome-wide identification of Pseudomonas aeruginosa exported proteins using a consensus computational strategy combined with a laboratory-based PhoA fusion screen. Genome Res 2005; 15: 321-9.
4. Gustin JK, Kessler E, Ohman DE. A substitution at His-120 in the LasA protease of Pseudomonas aeruginosa blocks enzymatic activity without affecting propeptide processing or extracellular secretion. J Bacteriol 1996; 178: 6608-17.
5. Kessler E, Safrin M, Peretz M et al. Identification of cleavage sites involved in proteolytic processing of Pseudomonas aeruginosa preproelastase. FEBS Lett 1992; 299: 291-3.
6. Chaddock AM, Mant A, Karnauchov I et al. A new type of signal peptide: central role of a twin-arginine motif in transfer signals for the delta pH-dependent thylakoidal protein translocase. EMBOJ 1995; 14: 2715-22.
7. Waite RD, Rose RS, Rangarajan M et al. Pseudomonas aeruginosa possesses two putative type I signal peptidases, LepB and PA1303, each with distinct roles in physiology and virulence. J Bacteriol 2012; 194: 4521-36.
8. Cregg KM, Wilding I, Black MT. Molecular cloning and expression of the spsB gene encoding an essential type I signal peptidase from Staphylococcus aureus. J Bacteriol 1996; 178: 5712-8.
9. Date T. Demonstration by a novel genetic technique that leader peptidase is an essential enzyme of Escherichia coli. J Bacteriol 1983; 154: 76-83.
10. Zhang YB, Greenberg B, Lacks SA. Analysis of a Streptococcus pneumoniae gene encoding signal peptidase I and overproduction of the enzyme. Gene 1997; 194: 249-55.
11. Auclair SM, Bhanu MK, Kendall DA. Signal peptidase I: cleaving the way to mature proteins. Protein Sci 2012; 21: 13-25.
12. Dalbey RE, Lively MO, Bron S et al. The chemistry and enzymology of the type I signal peptidases. Protein Sci 1997; 6: 1129-38.
13. Black MT, Bruton G. Inhibitors of bacterial signal peptidases. Curr Pharm Des 1998; 4: 133-54.
14. Luo C, Roussel P, Dreier J et al. Crystallographic analysis of bacterial signal peptidase in ternary complex with arylomycin A2 and a b-sultam inhibitor. Biochemistry 2009; 48: 8976-84.
15. Roberts TC, Schallenberger MA, Liu J et al. Initial efforts toward the optimization of arylomycins for antibiotic activity. J Med Chem 2011; 54: 4954-63.
16. Bockstael K, Geukens N, Rao CV et al. An easy and fast method for the evaluation of Staphylococcus epidermidis type I signal peptidase inhibitors. J Microbiol Meth 2009; 78: 231-7.
17. Kulanthaivel P, Kreuzman AJ, Strege MA et al. Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I. J Biol Chem 2004; 279: 36250-8.
18. Roberts TC, Smith PA, Cirz RT et al. Structural and initial biological analysis of synthetic arylomycin A2. J Am Chem Soc 2007; 129: 15830-8.
19. Barbosa MD, Lin S, Markwalder JA et al. Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro. Antimicrob Agents Chemother 2002; 46: 3549-54.
20. Ollinger J, O'Malley T, Ahn J et al. Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions. J Bacteriol 2012; 194: 2614-9.
21. Parsons YN, Panagea S, Smart CH et al. Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Clin Microbiol 2002; 40: 4607-11.
22. Smart CH, Walshaw MJ, Hart CA et al. Use of suppression subtractive hybridization to examine the accessory genome of the Liverpool cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 677-88.
23. Qiu D, Damron FH, Mima T et al. PBAD-based shuttle vectors for functional analysis of toxic and highly regulated genes in Pseudomonas and Burkholderia spp. and other bacteria. Appl Environ Microbiol 2008; 74: 7422-6.
24. Rao S, Bockstael K, Nath S et al. Enzymatic investigation of the Staphylococcus aureus type I signal peptidase SpsB-implications for the search for novel antibiotics. FEBS J 2009; 276: 3222-34.
25. Yoshimura F, Nikaido H. Permeability of Pseudomonas aeruginosa outer membrane to hydrophilic solutes. J Bacteriol 1982; 152: 636-42.
26. Tsubery H, Ofek I, Cohen S et al. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gram-negative bacteria. J Med Chem 2000; 43: 3085-92.
27. Li XZ, Zhang L, Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 433-6.
28. Wareham DW, Gordon NC, Hornsey M. In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 2011; 66: 1047-51.
29. Lee HJ, Bergen PJ, Bulitta JB et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57: 3738-45.
30. Timurkaynak F, Can F, Azap OK et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27: 224-8.
31. Hornsey M, Longshaw C, Phee L et al. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 2012; 56: 3080-5.
32. Smith PA, Roberts TC, Romesberg FE. Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations. Chem Biol 2010; 17: 1223-31.
33. Luke I, Handford JI, Palmer T et al. Proteolytic processing of Escherichia coli twin-arginine signal peptides by LepB. ArchMicrobiol 2009; 191: 919-25.
34. Jacobs MA, Alwood A, Thaipisuttikul I et al. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2003; 100: 14339-44.
35. Whiley RA, Sheikh NP, Mushtaq N et al. Differential potentiation of the virulence of the Pseudomonas aeruginosa cystic fibrosis liverpool epidemic strain by oral commensal streptococci. J Infect Dis 2014; 209: 769-80.
36. Hornsey M, Phee L, Stubbings W et al. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Int J Antimicrob Agents 2013; 42: 343-6.
37. Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2010; 54: 5316-22.
38. Hornsey M, Ellington MJ, Doumith M et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother 2010; 65: 1589-93.
39. Betts JW, Phee LM,Woodford N et al. Activity of colistin in combination with tigecycline or rifampicin againstmultidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2014; doi:10.1007/s10096-014-2101-3.
40. Le J, Castanheira M, Burgess DS et al. Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California. J Clin Microbiol 2010; 48: 623-5.
41. Lammertyn E, Van Mellaert L, Meyen E et al. Molecular and functional characterization of type I signal peptidase from Legionella pneumophila. Microbiology 2004; 150: 1475-83.